Cargando…
A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale
Certain population groups are known to have higher than average anal cancer risk, namely persons living with HIV (PLHIV), men who have sex with men (MSM), women diagnosed with human papillomavirus (HPV)‐related gynecological precancerous lesions or cancer, solid organ transplant recipients (SOTRs) a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689909/ https://www.ncbi.nlm.nih.gov/pubmed/32621759 http://dx.doi.org/10.1002/ijc.33185 |
_version_ | 1783613958644563968 |
---|---|
author | Clifford, Gary M. Georges, Damien Shiels, Meredith S. Engels, Eric A. Albuquerque, Andreia Poynten, Isobel Mary de Pokomandy, Alexandra Easson, Alexandra M. Stier, Elizabeth A. |
author_facet | Clifford, Gary M. Georges, Damien Shiels, Meredith S. Engels, Eric A. Albuquerque, Andreia Poynten, Isobel Mary de Pokomandy, Alexandra Easson, Alexandra M. Stier, Elizabeth A. |
author_sort | Clifford, Gary M. |
collection | PubMed |
description | Certain population groups are known to have higher than average anal cancer risk, namely persons living with HIV (PLHIV), men who have sex with men (MSM), women diagnosed with human papillomavirus (HPV)‐related gynecological precancerous lesions or cancer, solid organ transplant recipients (SOTRs) and patients with autoimmune diseases. Our aim was to provide robust and comparable estimates of anal cancer burden across these groups. Summary incidence rates (IRs), as cases per 100 000 person‐years (py), were calculated by fixed‐effects meta‐analysis. IRs were 85 (95% confidence interval [CI] = 82‐89) for HIV‐positive MSM (n = 7 studies; 2 229 234 py), 32 (95% CI = 30‐35) for non‐MSM male PLHIV (n = 5; 1626 448 py) and 22 (95% CI = 19‐24) for female PLHIV (n = 6; 1 472 123 py), with strong variation by age (eg, from 16.8 < 30 years to 107.5 ≥ 60 years for HIV‐positive MSM). IR was 19 (95% CI = 10‐36) in HIV‐negative MSM (n = 2; 48 135 py). Anal cancer IRs were much higher after diagnosis of vulvar (IR = 48 [95% CI = 38‐61]; n = 4; 145 147 py) than cervical (9 [95% CI = 8‐12]; n = 4; 779 098 py) or vaginal (IR = 10 [95% CI = 3‐30]; n = 4; 32 671) cancer, with equivalent disparity after respective precancerous lesions. IR was 13 (95% CI = 12‐15) in SOTRs (n = 5; 1 946 206 py), reaching 24.5 and 49.6 for males and females >10 years after transplant. Anal cancer IRs were 10 (95% CI = 5‐19), 6 (95% CI = 3‐11) and 3 (95% CI = 2‐4) for systemic lupus erythematosus, ulcerative colitis and Crohn's disease, respectively. In conclusion, a unifying anal cancer risk scale, based upon comprehensive meta‐analysis, can improve prioritization and standardization in anal cancer prevention/research initiatives, which are in their public health infancy. |
format | Online Article Text |
id | pubmed-7689909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76899092020-12-08 A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale Clifford, Gary M. Georges, Damien Shiels, Meredith S. Engels, Eric A. Albuquerque, Andreia Poynten, Isobel Mary de Pokomandy, Alexandra Easson, Alexandra M. Stier, Elizabeth A. Int J Cancer Cancer Epidemiology Certain population groups are known to have higher than average anal cancer risk, namely persons living with HIV (PLHIV), men who have sex with men (MSM), women diagnosed with human papillomavirus (HPV)‐related gynecological precancerous lesions or cancer, solid organ transplant recipients (SOTRs) and patients with autoimmune diseases. Our aim was to provide robust and comparable estimates of anal cancer burden across these groups. Summary incidence rates (IRs), as cases per 100 000 person‐years (py), were calculated by fixed‐effects meta‐analysis. IRs were 85 (95% confidence interval [CI] = 82‐89) for HIV‐positive MSM (n = 7 studies; 2 229 234 py), 32 (95% CI = 30‐35) for non‐MSM male PLHIV (n = 5; 1626 448 py) and 22 (95% CI = 19‐24) for female PLHIV (n = 6; 1 472 123 py), with strong variation by age (eg, from 16.8 < 30 years to 107.5 ≥ 60 years for HIV‐positive MSM). IR was 19 (95% CI = 10‐36) in HIV‐negative MSM (n = 2; 48 135 py). Anal cancer IRs were much higher after diagnosis of vulvar (IR = 48 [95% CI = 38‐61]; n = 4; 145 147 py) than cervical (9 [95% CI = 8‐12]; n = 4; 779 098 py) or vaginal (IR = 10 [95% CI = 3‐30]; n = 4; 32 671) cancer, with equivalent disparity after respective precancerous lesions. IR was 13 (95% CI = 12‐15) in SOTRs (n = 5; 1 946 206 py), reaching 24.5 and 49.6 for males and females >10 years after transplant. Anal cancer IRs were 10 (95% CI = 5‐19), 6 (95% CI = 3‐11) and 3 (95% CI = 2‐4) for systemic lupus erythematosus, ulcerative colitis and Crohn's disease, respectively. In conclusion, a unifying anal cancer risk scale, based upon comprehensive meta‐analysis, can improve prioritization and standardization in anal cancer prevention/research initiatives, which are in their public health infancy. John Wiley & Sons, Inc. 2020-07-29 2021-01-01 /pmc/articles/PMC7689909/ /pubmed/32621759 http://dx.doi.org/10.1002/ijc.33185 Text en © 2020 International Agency for Research on Cancer (IARC/WHO); licensed by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Cancer Epidemiology Clifford, Gary M. Georges, Damien Shiels, Meredith S. Engels, Eric A. Albuquerque, Andreia Poynten, Isobel Mary de Pokomandy, Alexandra Easson, Alexandra M. Stier, Elizabeth A. A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale |
title | A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale |
title_full | A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale |
title_fullStr | A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale |
title_full_unstemmed | A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale |
title_short | A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale |
title_sort | meta‐analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale |
topic | Cancer Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689909/ https://www.ncbi.nlm.nih.gov/pubmed/32621759 http://dx.doi.org/10.1002/ijc.33185 |
work_keys_str_mv | AT cliffordgarym ametaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT georgesdamien ametaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT shielsmerediths ametaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT engelserica ametaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT albuquerqueandreia ametaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT poyntenisobelmary ametaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT depokomandyalexandra ametaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT eassonalexandram ametaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT stierelizabetha ametaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT cliffordgarym metaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT georgesdamien metaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT shielsmerediths metaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT engelserica metaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT albuquerqueandreia metaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT poyntenisobelmary metaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT depokomandyalexandra metaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT eassonalexandram metaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale AT stierelizabetha metaanalysisofanalcancerincidencebyriskgrouptowardaunifiedanalcancerriskscale |